Paediatric metanephric tumours: a clinicopathological and molecular characterisation.


Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 29 07 2019
revised: 05 02 2020
accepted: 15 04 2020
pubmed: 7 5 2020
medline: 17 6 2020
entrez: 7 5 2020
Statut: ppublish

Résumé

To characterize metanephric tumours in children, we performed a literature review investigating paediatric metanephric adenomas (MA), metanephric stromal tumours (MST) and metanephric adenofibromas (MAF). Including two patients from our own institution (MA, MAF), 110 individual cases (41 MA, 20 MAF, 49 MST) were identified. Additionally, fifteen composite tumours were identified, with areas of MA/MAF and Wilms tumour (WT) or papillary carcinoma. No distinct clinical or radiological features could be defined. In pure metanephric tumours, histologically proven distant metastases were reported once (MA), relapse was reported once (MST) and one tumour-related death occurred (MST). Somatic BRAF-V600E mutations were tested in 15 cases, and identified in 3/6 MA, 3/3 MAF, and 6/6 MST. In our institution the MA harboured a somatic KRAS-G12R mutation. Overall, paediatric metanephric tumours are difficult to discriminate from other renal tumours at presentation, behave relatively benign, and the occurrence of composite tumours warrants analysis of underlying (genetic) pathways.

Identifiants

pubmed: 32371339
pii: S1040-8428(20)30108-6
doi: 10.1016/j.critrevonc.2020.102970
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
KRAS protein, human 0
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102970

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Dominique V C de Jel (DVC)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Janna A Hol (JA)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Electronic address: j.hol@prinsesmaximacentrum.nl.

Ariadne H A G Ooms (AHAG)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Department of Pathology, Pathan, Rotterdam, The Netherlands.

Ronald R de Krijger (RR)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Department of Pathology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.

Marjolijn C J Jongmans (MCJ)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Department of Clinical Genetics, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.

Annemieke S Littooij (AS)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Department of Radiology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.

Jarno Drost (J)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Oncode Institute, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Martine van Grotel (M)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Marry M van den Heuvel-Eibrink (MM)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH